Litigation Details for BTcP Pharma v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
✉ Email this page to a colleague
BTcP Pharma v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-09-13 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | |
| Jury Demand | None | Referred To | |
| Parties | INSYS THERAPEUTICS, INC. | ||
| Patents | 10,016,403; 8,486,972; 8,486,973; 8,835,459; 8,835,460; 9,241,935; 9,289,387; 9,642,797; 9,642,844 | ||
| Attorneys | Tara Mythri Raghavan | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in BTcP Pharma v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for BTcP Pharma v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-09-13 | 1 | United States Patent Nos. 8,486,972 (“the ’972 patent”); 8,486,973 (“the ’973 patent”); 8,835,459 (“…(“the ’459 patent”); 8,835,460 (“the ’460 patent”); 9,241,935 (“the ’935 patent”); 9,289,387 (“the ’387…’387 patent”); 9,642,797 (“the ’797 patent”); and 9,642,844 (“the ’844 patent”); (collectively, “the …the ’973 patent and two claims of the ’844 patent, but not the other claims in those patents. Further…the patents-in-suit”). (Exhibits A–H.) This action arises under the Patent Laws of the United States, 35 | External link to document | |
| 2017-09-13 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,486,972 B2; 8,486,973 B2; 8,835,459…13 September 2017 1:17-cv-01303 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
